Mammary Cell News Volume 10.41 | Oct 18 2018

TOP STORY

Synthetic Lethality between HER2 and Transaldolase in Intrinsically Resistant HER2-Positive Breast Cancers

Researchers performed a CRISPR/Cas9-mediated loss-of-function genetic profiling and identified TALDO1, which encoded the rate-limiting transaldolase enzyme in the non-oxidative pentose phosphate pathway, as essential for cellular survival following pharmacological HER2 blockade. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Profilin-1 Deficiency Leads to SMAD3 Upregulation and Impaired 3D Outgrowth of Breast Cancer Cells

Filopodial protrusion formation and single cell outgrowth of breast cancer cells (BCCs) were assessed using a 3D matrigel culture that accurately predicted dormant vs metastatic outgrowth phenotypes of BCCs in certain microenvironments. [Br J Cancer] Abstract

Breast Osteoblast-Like Cells: A New Biomarker for the Management of Breast Cancer

Scientists investigated the relationship between the expression of the main in situ markers of breast cancer and the presence of breast osteoblast-like cells. [Br J Cancer] Abstract

Positive Feedback Loop between Mitochondrial Fission and Notch Signaling Promotes Survivin-Mediated Survival of TNBC Cells

Scientists reported that mitochondrial fission was significantly increased in breast cancer (BC) tissues, especially in triple negative BC (TNBC) tissues, when compared with that in the corresponding peritumor tissues. [Cell Death Dis] Full Article

YLT-11, a Novel PLK4 Inhibitor, Inhibits Human Breast Cancer Growth via Inducing Maladjusted Centriole Duplication and Mitotic Defect

The effects of YLT-11 on breast cancer cells and the associated mechanism were investigated. In vitro, YLT-11 exhibited significant antiproliferation activities against breast cancer cells. [Cell Death Dis] Full Article

Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells

Knockdown of Grb2-associated binding protein 2 (Gab2) suppressed PI3K/AKT and MAPK/ERK pathway activity. Gab2 ablation also reduced the stemness of HER2-overexpressing breast cancer cells. [Cell Physiol Biochem] Full Article

Cyclin B1 Stability Is Increased by Interaction with BRCA1, and Its Overexpression Suppresses the Progression of BRCA1-Associated Mammary Tumors

Investigators demonstrated that BRCA1 interacted with cyclin B1, a crucial cell cycle regulator, and that their interaction was modulated by DNA damage and cell cycle phase. [Exp Mol Med] Full Article

MYC and DNMT3A-Mediated DNA Methylation Represses MicroRNA-200b in Triple Negative Breast Cancer

Investigators found that MYC proto-oncogene, bHLH transcription factor (MYC) and DNA methyltransferase 3A (DNMT3A) were highly expressed in triple-negative breast cancer tissues compared with other breast cancer subtypes, while miR-200b expression was inhibited significantly. [J Cell Mol Med] Full Article

Single Molecule Localization Microscopy Coupled with Touch Preparation for the Quantification of Trastuzumab-Bound HER2

Trastuzumab was used to directly detect human epidermal growth factor receptor 2 (HER2) with quantitative single molecule localization microscopy. [Sci Rep] Full Article

Endocrine Therapy-Resistant Breast Cancer Model Cells Are Inhibited by Soybean Glyceollin I through Eleanor Non-coding RNA

Scientists prepared a polyphenol, glyceollin I from stressed soybeans, and identified it as a major inhibitor of the ESR1 locus enhancing and activating non-coding RNA (Eleanor) RNA cloud and ESR1 mRNA transcription. The inhibition was independent of estrogen receptor, unlike one by resveratrol. [Sci Rep] Full Article

TIP60: An Actor in Acetylation of H3K4 and Tumor Development in Breast Cancer

Researchers showed that an underexpression of TIP60 could contribute to a reduction of H3K4 acetylation in breast cancer. [Epigenomics] Abstract

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Optimal Treatment of Early Stage HER2-Positive Breast Cancer

Investigators summarize the background and latest evidence on the current management of early stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer and present novel perspectives on its management. [Cancer] Abstract

HER2 in Stemness and Epithelial-Mesenchymal Plasticity of Breast Cancer

The author discusses the expression and regulation of HER2 in cancer stem cells of different sub-types of breast cancer and relationships of the receptor with both the circuits of stemness and epithelial-mesenchymal plasticity. [Clin Transl Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase II Combination Trial to Evaluate Effector’s Tomivosertib (eFT508) with KEYTRUDA^® (Pembrolizumab) for Metastatic Triple Negative Breast Cancer

The triple negative breast cancer trial will expand the current tomivosertib Phase II clinical trial program, allowing eFFECTOR to explore a combination with KEYTRUDA for an indication in which neither drug is yet approved. [eFFECTOR Therapeutics] Press Release

Celcuity Announces Clinical Trial Collaboration with Puma Biotechnology and West Cancer Center

This open-label Phase II trial will evaluate the efficacy and safety of Puma’s drug, neratinib, and chemotherapy in up to 27 early stage triple-negative breast cancer patients selected with Celcuity’s CELx HER2 Signaling Function Test. [Celcuity Inc. (Business Wire, Inc.)] Press Release

Myriad Receives FDA Approval of BRACAnalysis CDx^® as Companion Diagnostic for Pfizer’s TALZENNA^® (Talazoparib)

Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx^® to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are eligible for treatment with Pfizer’s poly ADP ribose polymerase inhibitor, talazoparib. [Myriad Genetics, Inc.] Press Release

Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People with HER2-Positive Early Breast Cancer with Residual Disease after Neoadjuvant Treatment

Genentech, Inc. announced the Phase III KATHERINE study met its primary endpoint, showing ado-trastuzumab emtansine as a single agent significantly reduced the risk of disease recurrence or death compared to trastuzumab as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. [Genentech, Inc.] Press Release

China Awaits Controversial Blacklist of ‘Poor Quality’ Journals

A proposal by the Chinese government to create a national blacklist of journals is creating much debate among the country’s scientists, who are still waiting for the list to be revealed, five months after the plan to create it was announced. [Nature News] Editorial

‘We Are Headed for a Very Dark Period.’ Brazil’s Researchers Fear Election of Far-Right Presidential Candidate

Beset by economic woes and dissatisfied with the left-wing politicians in power for most of the past 15 years, Brazil appears poised to make a hard turn and elect a far-right candidate, Jair Bolsonaro, as its next president. His rapid ascent has unnerved local researchers, who worry about the future of Brazilian science, the protection of the country’s biodiversity, and its role in the global struggle against climate change. [ScienceInsider] Editorial

Outsider Takes Helm at Indian Research Giant

Shekhar Mande, a structural biologist, took over as director-general of India’s Council of Scientific and Industrial Research (CSIR), headquartered in New Delhi, which operates a network of 40 research labs around the country. Mande is the first outsider to take on the top job at CSIR since 1984. [ScienceInsider] Editorial

NEW Canadian Breast Cancer Symposium
June 13-14, 2019
Toronto, Ontario, Canada

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Novel Cancer Gene and Therapy (University of Notre Dame)

NEW Research Associate – Immunology (King’s College London)

NEW Research Associate – CAR T-Cell Immunotherapy (King’s College London)

Epigenetic Reprogramming of Enhancers During Breast Cancer Progression (Università degli Studi di Trento)

Postdoctoral Fellowship – Epigenetics and RNA Biology (Umeå University)

Postdoctoral Research Fellow – Mammary Stem Cell Biology (University of Southampton)

Team Leader – ER Positive Breast Cancer (Institute of Cancer Research)

Assistant/Associate/Professor – Department of Cancer Biology (University of Cincinnati)

Postdoctoral Fellow – Immunotherapy of Breast Cancer (Boston University School of Medicine)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine)

Postdoctoral Position – Cancer Biology (GIGA – Universite de Liege)

Cancer Faculty Investigators – Breast Cancer (The University of Alabama)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.